Long-Term Debt: Caribou Bio (CRBU)

Brandmark of Caribou Biosciences, Inc (CRBU)

Caribou Biosciences (CRBU) utilizes the innovative chRDNA method for ultra-precise genome editing, which minimizes the risk of off-target mutations during therapy. The operating model relies on external partners for cell batch production, eliminating manufacturing disruptions. The market dynamics reflected in the quotes on GURU.Markets show a value of 0.03. Business success is based on lymphoma test results and the robust protection of its patents.

CRBU (Caribou Bio) Company Long-Term Debt history from 07/04/2022 to 11/01/2026

Caribou Bio - analytical breakdowns and key metrics (CRBU)

- current quotes and average value forecast:
Stock Quotes cariboubio.com|CRBU - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Caribou Biosciences|CRBU - Total Company Value
- book capitalization data:
Net Assets per Single Share Caribou Biosciences|CRBU - Company Book Value|Market-to-Book Ratio cariboubio.com|CRBU - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Caribou Biosciences|CRBU - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Caribou Biosciences, Inc|CRBU - Company Total Debt|Debt to Net Assets Ratio Caribou Biosciences|CRBU - Company Long-Term Debts|Company Current Liabilities Caribou Biosciences|Immediate Liquidity cariboubio.com
- net income and valuation multiples indicators:
CRBU - Company Net Income
Fundamental company valuation:cariboubio.com
Core merchandise of Caribou Biosciences, Inc.

A portfolio analyst utilizes this indicator to verify the issuer's credit quality and solvency. For Caribou Biosciences (CRBU), the absence of a heavy debt burden is critical due to high CRISPR research costs and patent risks. An analysis of the firm's long-term borrowings captures the actual volume of long-term liabilities in real-time. A decrease in this metric confirms financial autonomy, while an increase signals the raising of capital to scale development.

Who Caribou Biosciences competes with

LEGN - Company Long-Term Liabilities|SANA - Company Long-Term Debt|Long-Term Debt Autolus Therapeutics PLC|Allogene Therapeutics Inc (ALLO) - Company Long-Term Debt|RNAC (Selecta Biosciences Inc.) - Company Long-Term Debt|Company Long-Term Debt Cellectis SA|Long-Term Debt instilbio.com TIL|Company Long-Term Debts GNTA|centurytx.com (IPSC) - Long-Term Indebtedness|Jasper Therapeutics, Inc. - Company Long-Term Liabilities|Senti Bio (SNTI) - Long-Term Debt|ADAP: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings CERO (CERo Therapeutics)|TCRT: Company Long-Term Debts|Company Long-Term Liabilities Achilles Therapeutics plc|CRGX (Cargo Therapeutics) - Company Long-Term Debts|Long-Term Debt Poseida Corp PSTX|Company Long-Term Debt 2seventy bio, Inc. (TSVT)|Company Long-Term Debt GRCL (gracellbio.com)